The NR2F2 antibody is a crucial tool for studying the nuclear receptor subfamily 2 group F member 2 (NR2F2), also known as COUP-TFII (Chicken Ovalbumin Upstream Promoter Transcription Factor 2). NR2F2 is a ligand-dependent transcription factor involved in embryonic development, cell differentiation, and metabolic regulation. It plays key roles in angiogenesis, organogenesis, and stem cell maintenance by modulating target gene expression. Dysregulation of NR2F2 is linked to cancers (e.g., prostate, breast, ovarian), metabolic disorders, and cardiovascular diseases. Researchers use NR2F2 antibodies in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to detect its expression, localization, and DNA-binding activity in tissues or cultured cells. These antibodies help elucidate NR2F2's molecular mechanisms in disease models, developmental biology, and regenerative medicine. Commercial NR2F2 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes (e.g., N-terminal or C-terminal regions). Validation data (e.g., knockout controls, peptide blocking) are critical to ensure specificity. Its conserved structure across species allows cross-reactivity in human, mouse, and rat samples. Ongoing research leverages these antibodies to explore NR2F2's dual role as an oncogene or tumor suppressor, depending on cellular context, underscoring its therapeutic potential.